Gwynedd, United Kingdom

Juma′ A Raheem Najeem Al-Dulayy-mi


Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2014

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Juma′ A Raheem Najeem Al-Dulayy-mi: Innovator in Therapeutic Compounds

Introduction

Juma′ A Raheem Najeem Al-Dulayy-mi is a notable inventor based in Gwynedd, GB. He has made significant contributions to the field of therapeutic compounds, particularly in the treatment of diseases related to the immune system. His innovative work has led to the development of a unique compound that holds promise for medical applications.

Latest Patents

Juma′ A Raheem Najeem Al-Dulayy-mi holds 1 patent for his invention titled "Compounds for use in therapy." This patent describes a compound of formula (I) designed for the treatment of immune system diseases. The compound features various moieties, including alkyl, alkenyl, and aryl groups, which can be substituted and have a range of carbon atoms. The complexity of the compound's structure highlights its potential effectiveness in therapeutic applications.

Career Highlights

Throughout his career, Juma′ A Raheem Najeem Al-Dulayy-mi has worked with esteemed institutions such as Bangor University and Universiteit Gent. His experience in these academic environments has allowed him to collaborate with leading researchers and contribute to advancements in therapeutic research.

Collaborations

Juma′ A Raheem Najeem Al-Dulayy-mi has collaborated with notable colleagues, including Mark Stephen Baird and Cornelias Theunissen. These partnerships have enriched his research and expanded the impact of his work in the field of immunology.

Conclusion

Juma′ A Raheem Najeem Al-Dulayy-mi is a distinguished inventor whose work in therapeutic compounds showcases his commitment to advancing medical science. His innovative contributions continue to inspire future research in the treatment of immune system diseases.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…